Wockhardt informs about press release

13 Jan 2025 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release ‘Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem-Resistant Gram-Negative Pathogens’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.

Wockhardt Share Price

1418.45 -20.90 (-1.45%)
03-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1770.10
Dr. Reddys Lab 1151.25
Cipla 1495.15
Lupin 2094.50
Zydus Lifesciences 901.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...